Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Everolimus - Abbott

Drug Profile

Everolimus - Abbott

Alternative Names: Absorb; Absorb BVS; Absorb™ Bioresorbable Vascular Scaffold; Affinitor; Affinitor Dispersible; Afinitor; Afinitor DISPERZ; Afinitor Disperz; Certican; Esprit BVS; Promus; Promus Element; Promus Premier; RAD; RAD-001; SDZ RAD; Synergy; Synergy-everolimus-eluting-stent; Votubia; Xience nano; Xience Prime; Xience V; Xience Xpedition; Zortress

Latest Information Update: 02 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; University of Michigan Comprehensive Cancer Center
  • Developer Abbott Laboratories; Amgen; Assistance Publique Hopitaux de Paris; Boston Scientific Corporation; Dana-Farber Cancer Institute; Genentech; Hannover Medical School; Italian Trials in Medical Oncology; National Cancer Institute (USA); New York University School of Medicine; Novartis; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of California, Davis; University of Pittsburgh; University of Sydney; University of Texas M. D. Anderson Cancer Center; VU University Medical Center; Yale University
  • Class Anti-infectives; Anti-ischaemics; Antiepileptic drugs; Antineoplastics; Macrolides; Nootropics; Polyenes; Urologics; Vascular disorder therapies
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Partial epilepsies; Astrocytoma; Angiomyolipoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angiomyolipoma; Astrocytoma; Breast cancer; Coronary artery restenosis; Heart transplant rejection; Kidney disorders; Liver transplant rejection; Neuroendocrine tumours; Partial epilepsies; Renal cell carcinoma; Renal transplant rejection
  • Phase III Autosomal dominant polycystic kidney disease; Liver cancer; Myocardial infarction
  • Phase II Brain metastases; Cognition disorders; Endometrial cancer; Endometrial hyperplasia; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Glioma; Head and neck cancer; Hodgkin's disease; Meningioma; Neurofibromatosis 1; Neurofibromatosis 2; Non-small cell lung cancer; Pancreatic cancer; Plexiform neurofibroma; Sarcoma; Thymoma; Thyroid cancer; Tuberous sclerosis; Waldenstrom's macroglobulinaemia
  • Phase I/II Bladder cancer; Colorectal cancer; Oesophageal cancer; Respiratory tract infections
  • Phase I Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Cervical cancer; Haematological malignancies; Mantle-cell lymphoma; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
  • Discontinued Diffuse large B cell lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Pulmonary fibrosis; Rheumatoid arthritis

Most Recent Events

  • 28 Nov 2021 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Second-line therapy or greater) in USA (PO)
  • 28 Nov 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in France (PO)
  • 28 Nov 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Germany (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top